Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Rustamadji P.; Wiyarta E.; Pramono M.; Maulanisa S.C.
Rustamadji, Primariadewi (55321572200); Wiyarta, Elvan (57221521342); Pramono, Meike (59132495800); Maulanisa, Sinta Chaira (58189295400)
55321572200; 57221521342; 59132495800; 58189295400
Differential Effects of Anthracycline-based Neoadjuvant Chemotherapy on Stromal and Intratumoral FOXP3+ Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer of No Special Type
2024
Indonesian Biomedical Journal
16
2
135
143
8
0
Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Department of Medical Science, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Department of Surgical Oncology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia
Rustamadji P., Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Wiyarta E., Department of Medical Science, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Pramono M., Department of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia; Maulanisa S.C., Department of Surgical Oncology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jl. Salemba Raya No.6, Jakarta, 10430, Indonesia
BACKGROUND: Neoadjuvant chemotherapy (NAC) plays a crucial role in the management of invasive breast cancer with no special type (IBC-NST), with the immune system's response to cancer heavily relying on the dynamics between tumor-infiltrating lymphocytes (TILs) and cancer cells. In this study, the differential effects of anthracycline-based NAC on stromal and intratumoral foxhead box P3 (FOXP3+) TILs expressions were specifically examined. METHODS: In this cross-sectional study, 32 IBC-NST samples were evaluated for pre- and post-NAC FOXP3+ TIL expression as well as the changes of FOXP3+ TIL expression. Comprehensive data collection regarding subjects' age, tumor size, grade, lymphovascular invasion, regional lymph node metastasis, and receptor status were conducted. Immunohistochemistry was utilized to quantify FOXP3+ TILs. The stromal, intratumoral and total FOXP3+ TILs expression were then analyzed. RESULTS: Significant reductions in FOXP3+ TIL expression post-NAC were observed, with stromal FOXP3+ TILs showing a median decrease of 3.6 units in subjetcs aged >50 years (p=0.013) and a median decrease of 13.2 units in subjects with tumors >5 cm after NAC (p=0.006). In contrast, intratumoral FOXP3+ TILs remained relatively stable, with minor changes. The total FOXP3+ TIL expression, combining stromal and intratumoral components, was significantly decreased with a median of 13.0 units decreased to 5.3 units (p<0.001). CONCLUSION: This study highlights the significant reduction in stromal FOXP3+ TIL expression after NAC treatment in IBC-NST subjects, in contrast to the relatively stable intratumoral FOXP3+ TILs. Understanding these differences may guide future therapeutic strategies and improve treatment outcomes for IBC-NST. © 2024 The Prodia Education and Research Institute. This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC-BY-NC) License. All Rights Reserved.
biomarkers; chemotherapy; FOXP3; lymphocyte; prognostic; response
Prodia Education and Research Institute
20853297
Article
Q3
218
18286